Savara CFO Exercises Options as Company Approaches PDUFA Date for MOLBREEVI in Autoimmune Pulmonary Alveolar Proteinosis
Key Insights
Savara CFO David Lowrance exercised 580,187 options and sold 394,528 shares at approximately $5.68 per share on June 22, 2026, generating roughly $2.24 million.
The transaction occurred amid a 166.97% one-year stock return and two weeks after Lowrance announced his planned departure for health-related reasons.
Savara's BLA for MOLBREEVI (molgramostim), an inhaled GM-CSF therapy, has been accepted by the FDA with a PDUFA target action date of November 22, 2026.
Savara Inc. (NASDAQ: SVRA) is approaching a pivotal regulatory milestone as the FDA reviews its biologics license application (BLA) for MOLBREEVI (molgramostim), an inhaled GM-CSF therapy targeting autoimmune pulmonary alveolar proteinosis (search) (aPAP). The development comes as the company's Chief Financial Officer David Lowrance executed a significant option exercise and share sale, according to an SEC Form 4 filing dated June 22, 2026.
Lowrance exercised 580,187 options on Common Stock and subsequently sold 394,528 shares in the open market at a weighted average price of approximately $5.68 per share, yielding roughly $2.24 million. An additional 185,659 shares were withheld to cover tax obligations. Following the transaction, Lowrance retains direct ownership of 536,032 shares.
The sale represented 42.40% of Lowrance's total common stock holdings prior to the transaction and was materially larger than his previous sales. All shares sold and withheld were tied to the option exercise rather than discretionary open-market sales of previously held stock.
Context of the Executive Transition
Two weeks before the transaction, Savara announced that Lowrance will step down as chief financial and administrative officer in July 2026 for health-related reasons. Chief Operating Officer Robert Lutz is set to assume the CFO role. The timing and structure of the sale suggest the transaction was primarily driven by compensation mechanics and the upcoming leadership transition rather than a shift in confidence regarding the company's prospects.
The transaction occurred against a backdrop of strong share price appreciation, with Savara delivering a 166.97% one-year return as of June 22, 2026.
Regulatory Progress and Commercial Preparation
The larger narrative for investors centers on Savara's progress toward potential commercialization. The FDA has accepted the company's BLA for MOLBREEVI, with a Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026. Concurrently, European and U.K. regulatory reviews are underway.
Savara reported ending the first quarter with approximately $203 million in cash and short-term investments, plus access to up to an additional $150 million in non-dilutive capital contingent upon FDA approval. This financial position is designed to fund a potential product launch.
CEO Matt Pauls indicated that commercial planning is accelerating as the company prepares for what could become the first approved treatment for autoimmune pulmonary alveolar proteinosis (search), a rare respiratory disease characterized by surfactant accumulation in the alveoli.
MOLBREEVI and the aPAP Landscape
MOLBREEVI is an inhaled formulation of granulocyte-macrophage colony-stimulating factor (GM-CSF). Savara is developing the therapy for rare respiratory diseases, with aPAP as the lead indication currently in Phase III trials. Autoimmune pulmonary alveolar proteinosis (search) is an orphan indication with no currently approved pharmacologic treatments, positioning MOLBREEVI to address a significant unmet medical need should it secure regulatory approval.
Savara operates a clinical-stage biopharmaceutical model focused on advancing proprietary drug candidates through regulatory milestones, with the goal of generating future revenue through product approvals or strategic partnerships. The company targets patients with rare lung disorders, with specialty healthcare providers and hospitals anticipated as primary customers.